Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.

IF 2.5 4区医学 Q3 NEUROSCIENCES

Acta Neuropsychiatrica Pub Date : 2025-09-03 DOI:10.1017/neu.2025.10038

Hezekiah C T Au, Pak Ho Lam, Fateen Kabir, Chen Lily Huang, Christine E Dri, Gia Han Le, Angela T H Kwan, Sabrina Wong, Kayla M Teopiz, Roger S McIntyre

{"title":"Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.","authors":"Hezekiah C T Au, Pak Ho Lam, Fateen Kabir, Chen Lily Huang, Christine E Dri, Gia Han Le, Angela T H Kwan, Sabrina Wong, Kayla M Teopiz, Roger S McIntyre","doi":"10.1017/neu.2025.10038","DOIUrl":null,"url":null,"abstract":"Introduction: Extant literature indicated that glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may potentially reduce risk of opioid overdose in persons with opioid use disorders (OUDs). Herein, we conducted a comprehensive synthesis of the effects of GLP-1 and GLP-1 RAs on OUDs.Methods: We examined preclinical and clinical paradigms examining the effects of GLP-1 and GLP-1 RAs on OUD and OUD-associated behaviours (i.e. opioid self-administration, opioid-seeking behaviour). Relevant articles were retrieved from OVID (MedLine, Embase, AMED, PsychINFO, and JBI EBP Database), PubMed, and Web of Science from database inception to 1 May 2025. Primary studies (n = 10) examining the aforementioned effects associated with GLP-1 and GLP-1 RA administration were retrieved for analysis.Results: GLP-1 RAs (i.e. exenatide, liraglutide) reduced opioid-seeking behaviour (p < 0.05) and self-administration of opioid drugs (p < 0.05) in preclinical paradigms. In addition, results from human studies indicate that GLP-1 administration was associated with reducing the risk of opioid overdose in human studies (aIRR = 0.60, 95% CI [0.43, 0.83]).Conclusion: GLP-1 RAs may affect opioid self-administration as well as the risk for overdose as evidenced by both preclinical and clinical data. There is a need for adequate well-controlled studies to determine whether GLP-1 RAs may provide clinically meaningful improvement and risk reduction in persons living with OUDs.","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"e85"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2025.10038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Extant literature indicated that glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may potentially reduce risk of opioid overdose in persons with opioid use disorders (OUDs). Herein, we conducted a comprehensive synthesis of the effects of GLP-1 and GLP-1 RAs on OUDs.

Methods: We examined preclinical and clinical paradigms examining the effects of GLP-1 and GLP-1 RAs on OUD and OUD-associated behaviours (i.e. opioid self-administration, opioid-seeking behaviour). Relevant articles were retrieved from OVID (MedLine, Embase, AMED, PsychINFO, and JBI EBP Database), PubMed, and Web of Science from database inception to 1 May 2025. Primary studies (n = 10) examining the aforementioned effects associated with GLP-1 and GLP-1 RA administration were retrieved for analysis.

Results: GLP-1 RAs (i.e. exenatide, liraglutide) reduced opioid-seeking behaviour (p < 0.05) and self-administration of opioid drugs (p < 0.05) in preclinical paradigms. In addition, results from human studies indicate that GLP-1 administration was associated with reducing the risk of opioid overdose in human studies (aIRR = 0.60, 95% CI [0.43, 0.83]).

Conclusion: GLP-1 RAs may affect opioid self-administration as well as the risk for overdose as evidenced by both preclinical and clinical data. There is a need for adequate well-controlled studies to determine whether GLP-1 RAs may provide clinically meaningful improvement and risk reduction in persons living with OUDs.

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂治疗阿片类药物使用障碍：系统综述。

现有文献表明，胰高血糖素样肽-1 （GLP-1）和胰高血糖素样肽-1受体激动剂（GLP-1 RAs）可能潜在地降低阿片类药物使用障碍（OUDs）患者阿片类药物过量的风险。在此，我们全面综合了GLP-1和GLP-1 RAs对OUDs的影响。方法：我们检查了GLP-1和GLP-1 RAs对OUD和OUD相关行为（即阿片类药物自我给药，阿片类药物寻求行为）的影响的临床前和临床范例。从OVID （MedLine, Embase， AMED， PsychINFO和JBI EBP数据库），PubMed和Web of Science检索数据库建立至2025年5月1日的相关文章。我们检索了与GLP-1和GLP-1 RA给药相关的上述效应的初步研究（n = 10）进行分析。结果：GLP-1 RAs（即艾塞那肽、利拉鲁肽）可减少临床前患者的阿片寻求行为（p < 0.05）和阿片药物自我给药（p < 0.05）。此外，人类研究结果表明，在人类研究中，GLP-1给药与降低阿片类药物过量风险相关（aIRR = 0.60, 95% CI[0.43, 0.83]）。结论：GLP-1 RAs可能影响阿片类药物的自我给药以及过量的风险，临床前和临床数据均证实了这一点。有必要进行充分的对照研究，以确定GLP-1 RAs是否可以为oud患者提供有临床意义的改善和风险降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Neuropsychiatrica NEUROSCIENCES-PSYCHIATRY

自引率

5.30%

发文量

期刊介绍： Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.